Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
Asim Amin, Elizabeth R. Plimack, Marc S. Ernstoff, et al.
Journal for ImmunoTherapy of Cancer (2018) Vol. 6, Iss. 1
Open Access | Times Cited: 170

Showing 1-25 of 170 citing articles:

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Toni K. Choueiri, Thomas Powles, Mauricio Burotto, et al.
New England Journal of Medicine (2021) Vol. 384, Iss. 9, pp. 829-841
Open Access | Times Cited: 1354
Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy
Charles Pottier, Margaux Fresnais, Marie Gilon, et al.
Cancers (2020) Vol. 12, Iss. 3, pp. 731-731
Open Access | Times Cited: 433
Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma
Ann‐Lii Cheng, Chiun Hsu, Stephen L. Chan, et al.
Journal of Hepatology (2020) Vol. 72, Iss. 2, pp. 307-319
Open Access | Times Cited: 428
The Intersection between Tumor Angiogenesis and Immune Suppression
Osama E. Rahma, F. Stephen Hodi
Clinical Cancer Research (2019) Vol. 25, Iss. 18, pp. 5449-5457
Closed Access | Times Cited: 391
Targeting the HIF2–VEGF axis in renal cell carcinoma
Toni K. Choueiri, William G. Kaelin
Nature Medicine (2020) Vol. 26, Iss. 10, pp. 1519-1530
Closed Access | Times Cited: 356
Enhancing anti-tumour efficacy with immunotherapy combinations
Funda Meric‐Bernstam, James Larkin, Josep Tabernero, et al.
The Lancet (2020) Vol. 397, Iss. 10278, pp. 1010-1022
Closed Access | Times Cited: 303
Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities
Stephen P. Hack, Andrew X. Zhu, Yulei Wang
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 201
Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment
Yuxiao Song, Yang Fu, Qi Xie, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 199
Towards individualized therapy for metastatic renal cell carcinoma
Ritesh R. Kotecha, Robert J. Motzer, Martin H. Voss
Nature Reviews Clinical Oncology (2019) Vol. 16, Iss. 10, pp. 621-633
Closed Access | Times Cited: 185
Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier
Somayeh Vafaei, Angelina Olegovna Zekiy, Ramadhan Ado Khanamir, et al.
Cancer Cell International (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 166
Energy status dictates PD-L1 protein abundance and anti-tumor immunity to enable checkpoint blockade
Xiaoming Dai, Xia Bu, Yang Gao, et al.
Molecular Cell (2021) Vol. 81, Iss. 11, pp. 2317-2331.e6
Open Access | Times Cited: 153
Cancer combination therapies by angiogenesis inhibitors; a comprehensive review
Mohammad Javed Ansari, Dmitry Olegovich Bokov, Alexander Markov, et al.
Cell Communication and Signaling (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 127
First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis
Fahad Quhal, Keiichiro Mori, Andreas Bruchbacher, et al.
European Urology Oncology (2021) Vol. 4, Iss. 5, pp. 755-765
Closed Access | Times Cited: 123
Hot and cold tumors: Immunological features and the therapeutic strategies
Lianjie Wang, Hui Geng, Yujie Liu, et al.
MedComm (2023) Vol. 4, Iss. 5
Open Access | Times Cited: 96
Sunitinib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers
Juan Jin, Yuhao Xie, Jin-Shi Zhang, et al.
Drug Resistance Updates (2023) Vol. 67, pp. 100929-100929
Open Access | Times Cited: 82
Cabozantinib in Combination with Immunotherapy for Advanced Renal Cell Carcinoma and Urothelial Carcinoma: Rationale and Clinical Evidence
Paulo Gustavo Bergerot, Peter Lamb, Evelyn N. Wang, et al.
Molecular Cancer Therapeutics (2019) Vol. 18, Iss. 12, pp. 2185-2193
Closed Access | Times Cited: 110
Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages
Da‐Liang Ou, Chia-Wei Chen, Chia‐Lang Hsu, et al.
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 3, pp. e001657-e001657
Open Access | Times Cited: 100
Chemotherapeutic and targeted agents can modulate the tumor microenvironment and increase the efficacy of immune checkpoint blockades
Junyan Li, Yu‐Pei Chen, Ying‐Qin Li, et al.
Molecular Cancer (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 91
Targeting the PD-1/PD-L1 Pathway in Renal Cell Carcinoma
Solène‐Florence Kammerer‐Jacquet, Antoine Deleuze, Judikaël Saout, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 7, pp. 1692-1692
Open Access | Times Cited: 82
Neutrophils in the era of immune checkpoint blockade
Julien Faget, Solange Peters, Xavier Quantin, et al.
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 7, pp. e002242-e002242
Open Access | Times Cited: 79
Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents
Paola Ciciola, Priscilla Cascetta, Cataldo Bianco, et al.
Journal of Clinical Medicine (2020) Vol. 9, Iss. 3, pp. 675-675
Open Access | Times Cited: 76
Anti-angiogenesis therapy overcomes the innate resistance to PD-1/PD-L1 blockade in VEGFA-overexpressed mouse tumor models
Qiaohong Wang, Jingze Gao, Wen Di, et al.
Cancer Immunology Immunotherapy (2020) Vol. 69, Iss. 9, pp. 1781-1799
Open Access | Times Cited: 76
Immunomodulatory Roles of VEGF Pathway Inhibitors in Renal Cell Carcinoma
Laure Hirsch, Ronan Flippot, Bernard Escudier, et al.
Drugs (2020) Vol. 80, Iss. 12, pp. 1169-1181
Closed Access | Times Cited: 73
Updates on Immunotherapy and Immune Landscape in Renal Clear Cell Carcinoma
Myung‐Chul Kim, Jin Zeng, Ryan Kolb, et al.
Cancers (2021) Vol. 13, Iss. 22, pp. 5856-5856
Open Access | Times Cited: 59
First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis
Angela Aldin, Burcu Besiroglu, Anne Adams, et al.
Cochrane library (2023) Vol. 2023, Iss. 5
Open Access | Times Cited: 24
Page 1 - Next Page

Scroll to top